Search results for "therapy [Ciliopathies]"

showing 10 items of 2852 documents

Combined aerobic and resistance training decreases inflammation markers in healthy men

2017

Our primary aim was to study the effects of 24 weeks of combined aerobic and resistance training performed on the same day or on different days on inflammation markers. Physically active, healthy young men were randomly divided into three groups that performed: aerobic and resistance training consecutively in the same training session (SS) 2-3 days wk-1 or on alternating days (AD) 4-6 days wk-1 as well as control (C). The total training volume was matched in the training groups. The control group was asked to maintain their habitual physical activity and exercise level. Maximal leg press strength (1RM) and peak oxygen uptake (VO2peak ) were measured. Abdominal fat mass was estimated with du…

AdultLeptinMalemedicine.medical_specialtytulehdusarvotAdipokinePhysical Therapy Sports Therapy and RehabilitationPhysical exercise030204 cardiovascular system & hematologyliikunta03 medical and health sciences0302 clinical medicineOxygen Consumptionphysical exerciseInternal medicinemedicinelow-grade inflammationHumansOrthopedics and Sports MedicineResistinLeg pressta315ExerciseadipokinesChemokine CCL2InflammationbiologyAdiponectinbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaLeptinC-reactive proteinabdominal fatVO2 maxResistance Training030229 sport sciencesEndocrinologyC-Reactive Proteinbiology.proteinBody CompositionResistinAdiponectinbusinessBiomarkersScandinavian Journal of Medicine and Science in Sports
researchProduct

The role of adiponectin and leptin in the treatment of ovarian cancer patients

2019

Introduction: Ovarian cancer is most frequently detected in the advanced stage. Although its pathogenesis is not fully elucidated, it is assumed that body susceptibility and hormonal disorders are responsible. The role of some cytokines as predictors in the treatment process is still investigated. The aim of the study was to determine the relationship of adiponectin and leptin with the disease severity and response to chemotherapy. Material and methods: Forty-three ovarian cancer patients were treated by systemic treatment. Patients received 5–7 cycles of chemotherapy — paclitaxel/carboplatin with or without bevacizumab. Using standard ELISA kits before and after chemotherapy, adiponectin a…

AdultLeptinmedicine.medical_specialtyPaclitaxelBevacizumabEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipokine030209 endocrinology & metabolismGastroenterologyCarboplatin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyBlood serumInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedAged 80 and overOvarian NeoplasmsChemotherapyAdiponectinbusiness.industryLeptinMiddle Agedmedicine.diseaseCarboplatinBevacizumabTreatment OutcomechemistryFemaleAdiponectinOvarian cancerbusinessBiomarkershormones hormone substitutes and hormone antagonistsmedicine.drugEndokrynologia Polska
researchProduct

Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience.

2012

Abstract Aims The aim of this study is to evaluate factors associated with the outcome after surgical resection and to compare the efficacy of surgery to transarterial chemoembolisation (TACE) in patients with advanced intrahepatic cholangiocarcinoma (IHC). Materials and methods 273 patients with IHC treated in our department between 1997 and 2012 were included in our study. Patients were divided according to therapy into surgical ( n  = 130), TACE ( n  = 32), and systemic chemotherapy/best supportive care ( n  = 111) groups. Clinicopathological characteristics and survival were reviewed retrospectively. Results The 1-, 3-, and 5-year survival rates in patients after surgical resection were…

AdultLiver CirrhosisMalemedicine.medical_specialtyKaplan-Meier EstimateSingle CenterCholangiocarcinomaHepatic ArteryAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansChemoembolization TherapeuticLymph nodeIntrahepatic CholangiocarcinomaAgedRetrospective StudiesAged 80 and overUnivariate analysisAnalysis of Variancebusiness.industryBile ductLiver NeoplasmsRetrospective cohort studyGeneral MedicineMiddle AgedSurgerymedicine.anatomical_structureBile Ducts IntrahepaticTreatment OutcomeOncologyBile Duct NeoplasmsChemotherapy AdjuvantResection marginSurgeryFemalePositive Surgical MarginbusinessEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

The difference in risk of chronic pulmonary disease morbidity and mortality between former elite athletes and ordinary men in Finland.

2019

The impact of a history of competitive sports on later smoking behaviour and occurrence of chronic pulmonary diseases is poorly known. We investigated how a history of elite level sports predicted later pulmonary disease morbidity and mortality. Chronic pulmonary disease incidence was assessed from national hospital and cause-of-death registers from 1970 to 2015 among Finnish male former elite athletes (n = 2078) and matched controls (n = 1453) alive in 1970 (mean age 45.0 years). Hazard ratios (HRs) were calculated by Cox proportional hazards model. In 1985, cohort members reported on their smoking habits, engagement in physical activity/sports and physician-diagnosed chronic diseases. The…

AdultLung DiseasesMalemedicine.medical_specialtyChronic bronchitisCompetitive Behavior030209 endocrinology & metabolismPhysical Therapy Sports Therapy and RehabilitationComorbidity03 medical and health sciences0302 clinical medicineAge DistributionRisk FactorsInternal medicineCause of DeathmedicineHumansOrthopedics and Sports MedicineLongitudinal StudiesYoung adultExerciseFinlandProportional Hazards ModelsCOPDbiologyAthletesProportional hazards modelbusiness.industryHazard ratioSmoking030229 sport sciencesGeneral MedicineLength of StayMiddle Agedbiology.organism_classificationmedicine.disease3. Good healthSocioeconomic FactorsAthletesCohortChronic DiseasePhysical EndurancebusinessCohort studyEuropean journal of sport science
researchProduct

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-0…

2016

The aim of this clinical trial was to evaluate the impact of all-trans retinoic acid (ATRA) in combination with chemotherapy and to assess the NPM1 status as biomarker for ATRA therapy in younger adult patients (18–60 years) with acute myeloid leukemia (AML). Patients were randomized for intensive chemotherapy with or without open-label ATRA (45 mg/m2, days 6–8; 15 mg/m2, days 9–21). Two cycles of induction therapy were followed by risk-adapted consolidation with high-dose cytarabine or allogeneic hematopoietic cell transplantation. Due to the open label character of the study, analysis was performed on an intention-to-treat (ITT) and a per-protocol (PP) basis. One thousand one hundred pati…

AdultMale0301 basic medicineAcute promyelocytic leukemiaOncologymedicine.medical_specialtyNPM1Adolescentmedicine.medical_treatmentTretinoinYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansddc:610ChemotherapyAcute myeloid leukemiaHematologyAll-trans retinoic acidbusiness.industryMyeloid leukemiaInduction ChemotherapyHematologyGeneral MedicineMiddle Agedmedicine.disease3. Good healthSurgerySurvival RateTransplantationClinical trialLeukemia Myeloid AcuteTreatment Outcome030104 developmental biologyNucleophosmin-1Acute myeloid leukemia; All-trans retinoic acid; Nucleophosmin-1030220 oncology & carcinogenesisCytarabineFemaleOriginal ArticlebusinessNucleophosminFollow-Up Studiesmedicine.drug
researchProduct

Measurement of body composition in cancer patients using CT planning scan at the third lumbar vertebra

2019

Objective: the main objective was to assess body composition in terms of skeletal muscle index (SMI), myosteatosis, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and intermuscular adipose tissue (IMAT) as an adjunct of information provided by radiotherapy CT planning scan. Material and methods: a sample of 49 patients with lung and digestive cancers underwent a CT scan for radiotherapy treatment, which included measurements at the L3 region. Images were analyzed with a radiotherapy contouring software, using different Hounsfield Unit (HU) settings. Cross-sectional areas (cm2) were automatically computed by summing tissue pixels and multiplying by pixel surface area. Low …

AdultMale0301 basic medicineCT scanLung NeoplasmsRadioteràpiaMedicine (miscellaneous)030209 endocrinology & metabolismComputed tomographyDigestive System NeoplasmsBody composition03 medical and health sciences0302 clinical medicineHounsfield scalemedicineHumansAgedRetrospective StudiesCancerAged 80 and overThird lumbar vertebraLumbar Vertebrae030109 nutrition & dieteticsNutrition and DieteticsCt planningmedicine.diagnostic_testRadiotherapybusiness.industryRadiotherapy Planning Computer-AssistedCancerMiddle Agedmedicine.diseaseHighly sensitiveBody CompositionFemaleRadiotherapy treatmentSubcutaneous adipose tissueTomography X-Ray ComputedCàncer PacientsNuclear medicinebusiness
researchProduct

Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

2016

We explored the association of early tumor shrinkage (ETS) and non-ETS with efficacy of first-line and consecutive second-line treatment in patients with KRAS wild-type metastatic colorectal cancer treated in FIRE-3. Assessment of tumor shrinkage was based on the sum of longest diameters of target lesions, evaluated after 6 weeks of treatment. Shrinkage was classified as ETS (shrinkage by ≥ 20%), mETS (shrinkage by 0 to20%), mPD (minor progression0 to20%) and PD (progression ≥20%). Overall survival (OS) was 33.2 (95% CI 28.0-38.4) months in ETS patients, while non-ETS was associated with less favorable outcome (mETS 24.0 (95% CI 21.2-26.9) months, mPD 19.0 (95% CI 13.0-25.0) months, PD 12.8…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerLeucovorinCetuximabKaplan-Meier Estimatemedicine.disease_causeGastroenterologyDisease-Free SurvivalProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedShrinkageCetuximabbusiness.industryRemission InductionTumor shrinkageMiddle Agedmedicine.diseaseBevacizumabTreatment Outcome030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesisFOLFIRICamptothecinFemaleFluorouracilKRASColorectal Neoplasmsbusinessmedicine.drugInternational Journal of Cancer
researchProduct

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic aden…

2020

Abstract Background Chemotherapy is effective in metastatic pancreatic adenocarcinoma (mPA), but new approaches are still needed to improve patients' survival and quality of life. We have previously published good efficacy and tolerability results on a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI (5FU+irinotecan) regimen. In the present study, we evaluated the same sequence but replaced gemcitabine by the new gemcitabine + nab-paclitaxel standard first-line combination. Patients and methods We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status 0–2 to alternately receive gemcitab…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyPaclitaxelPopulationLeucovorinPhases of clinical researchAdenocarcinomaNeutropeniaIrinotecanDeoxycytidineGastroenterology03 medical and health sciences0302 clinical medicineAlbuminsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasiseducationAgededucation.field_of_studyDrug Substitutionbusiness.industryMiddle Agedmedicine.diseaseGemcitabineNeoadjuvant TherapyProgression-Free SurvivalGemcitabinePancreatic NeoplasmsIrinotecanTreatment Outcome030104 developmental biologyOncologyTolerability030220 oncology & carcinogenesisDisease ProgressionFOLFIRICamptothecinFemaleFluorouracilFrancebusinessFebrile neutropeniamedicine.drugEuropean Journal of Cancer
researchProduct

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer

2019

Abstract Background and objectives Pre-clinical data have shown that combining trifluridine/tipiracil with oxaliplatin enhances anti-tumour activity compared with either monotherapy. A phase I dose-escalation study was conducted to determine the maximum tolerated dose (MTD), recommended dose (RD) for phase II and pharmacokinetic profile of this combination in patients with metastatic colorectal cancer (mCRC) who had progressed after at least 1 prior line of treatment. Methods Using a 3 + 3 design, patients received escalating trifluridine/tipiracil doses from 25, then 30 and to 35 mg/m2 twice daily, days 1–5, q14 days, together with a fixed dose of 85 mg/m2 of oxaliplatin day 1, q14 days. A…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyPyrrolidinesMaximum Tolerated DoseNauseaTrifluridineNeutropeniaGastroenterologyTrifluridine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineUracilAdverse effectneoplasmsAgedTipiracilbusiness.industryMiddle Agedmedicine.diseaseOxaliplatinOxaliplatinDrug Combinations030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisVomitingFemalemedicine.symptomColorectal NeoplasmsbusinessThymineFebrile neutropeniamedicine.drugEuropean Journal of Cancer
researchProduct

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients

2016

Summary Analysis of a polymorphism in mature microRNA-608 (rs4919510) in rectal cancer patients enrolled in a randomized phase II clinical trial identified patient subpopulations who might benefit from the use of an intensified neo-adjuvant treatment strategy with Cetuximab.

AdultMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPathologyGenotypeColorectal cancermedicine.medical_treatmentOriginal ManuscriptSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmicroRNAmedicineHumansOncology & CarcinogenesisProgression-free survivalNeoadjuvant therapyAgedRetrospective StudiesCetuximabRectal Neoplasmsbusiness.industryChemoradiotherapyGeneral MedicineMiddle Agedmedicine.diseaseChemotherapy regimenNeoadjuvant Therapy3. Good healthRadiation therapyMicroRNAs030104 developmental biology030220 oncology & carcinogenesisFemalebusiness1112 Oncology And Carcinogenesismedicine.drug
researchProduct